Home > Insider Trading > Filing (0001012975-14-000340)

Filing Details

Accession Number:: 0001012975-14-000340
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2014-05-29 18:44:49
Reporting Period:: 2014-05-27

Filing Date:: 2014-05-29
Accepted Time:: 2014-05-29 18:44:49
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1463729	Receptos Inc.	RCPT	Pharmaceutical Preparations (2834)	264190792

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1569248	Kristina Burow	8725 West Higgins Road, Suite 290 Chicago IL 60631		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2014-05-27	3,418	$29.90	123,698	No	4	S	Indirect	See footnotes
Common Stock	Disposition	2014-05-28	3,914	$29.41	119,784	No	4	S	Indirect	See footnotes
Common Stock	Disposition	2014-05-29	1,607	$30.20	118,177	No	4	S	Indirect	See footnotes
Common Stock	Disposition	2014-05-27	55,353	$29.90	2,003,281	No	4	S	Indirect	See footnotes
Common Stock	Disposition	2014-05-28	63,386	$29.41	1,939,895	No	4	S	Indirect	See footnotes
Common Stock	Disposition	2014-05-29	26,020	$30.20	1,913,875	No	4	S	Indirect	See footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See footnotes
No	4	S	Indirect	See footnotes
No	4	S	Indirect	See footnotes
No	4	S	Indirect	See footnotes
No	4	S	Indirect	See footnotes
No	4	S	Indirect	See footnotes

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	13,333	Direct

Footnotes

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.585 to $30.21, inclusive. The reporting person takes to provide to RCPT, any security holder of RCPT, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), and (3) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.25 to $29.75, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.86, inclusive.
Beneficial ownership consists of an aggregate of 118,177 shares of common stock held by ARCH Venture Fund VI, L.P. ("ARCH Fund VI"). The sole general partner of ARCH Fund VI is ARCH Venture Partners VI, L.P. ("ARCH Partners VI"), which may be deemed to beneficially own the shares held by ARCH Fund VI. The sole general partner of ARCH Partners VI is ARCH Venture Partners VI, LLC ("ARCH VI LLC"), which may be deemed to beneficially own the shares held by ARCH Fund VI. ARCH Partners VI and ARCH VI LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
Beneficial ownership consists of 1,913,875 shares of common stock held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
The managing directors of ARCH VI LLC and ARCH VII LLC are Keith Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund VI and ARCH Fund VII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Kristina Burow owns an interest in ARCH Partners VI and ARCH Partners VII but does not have voting or investment control over the shares held by ARCH Fund VI or ARCH Fund VII and disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.